• Je něco špatně v tomto záznamu ?

Updated European Association of Urology Guidelines Regarding Adjuvant Therapy for Renal Cell Carcinoma

A. Bex, L. Albiges, B. Ljungberg, K. Bensalah, S. Dabestani, RH. Giles, F. Hofmann, M. Hora, MA. Kuczyk, TB. Lam, L. Marconi, AS. Merseburger, M. Staehler, A. Volpe, T. Powles,

. 2017 ; 71 (5) : 719-722. [pub] 20161213

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18010895

The European Association of Urology Renal Cell Carcinoma (RCC) guidelines panel updated their recommendation on adjuvant therapy in unfavourable, clinically nonmetastatic RCC following the recently reported results of a second randomised controlled phase 3 trial comparing 1-yr sunitinib to placebo for high-risk RCC after nephrectomy (S-TRAC). On the basis of conflicting results from the two available studies, the panel rated the quality of the evidence, the harm-to-benefit ratio, patient preferences, and costs. Finally, the panel, including representatives from a patient advocate group (International Kidney Cancer Coalition) voted and reached a consensus to not recommend adjuvant therapy with sunitinib for patients with high-risk RCC after nephrectomy. PATIENT SUMMARY: In two studies, sunitinib was given for 1 yr and compared to no active treatment (placebo) in patients who had their kidney tumour removed and who had a high risk of cancer coming back after surgery. Although one study demonstrated that 1 yr of sunitinib therapy resulted in a 1.2-yr longer time before the disease recurred, the other study did not show a benefit and it has not been shown that patients live longer. Despite having been diagnosed with high-risk disease, many patients remain without recurrence, and the side effects of sunitinib are high. Therefore, the panel members, including patient representatives, do not recommend sunitinib after tumour removal in these patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18010895
003      
CZ-PrNML
005      
20180404142400.0
007      
ta
008      
180404s2017 sz f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.eururo.2016.11.034 $2 doi
035    __
$a (PubMed)27986369
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Bex, Axel $u Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. Electronic address: a.bex@nki.nl.
245    10
$a Updated European Association of Urology Guidelines Regarding Adjuvant Therapy for Renal Cell Carcinoma / $c A. Bex, L. Albiges, B. Ljungberg, K. Bensalah, S. Dabestani, RH. Giles, F. Hofmann, M. Hora, MA. Kuczyk, TB. Lam, L. Marconi, AS. Merseburger, M. Staehler, A. Volpe, T. Powles,
520    9_
$a The European Association of Urology Renal Cell Carcinoma (RCC) guidelines panel updated their recommendation on adjuvant therapy in unfavourable, clinically nonmetastatic RCC following the recently reported results of a second randomised controlled phase 3 trial comparing 1-yr sunitinib to placebo for high-risk RCC after nephrectomy (S-TRAC). On the basis of conflicting results from the two available studies, the panel rated the quality of the evidence, the harm-to-benefit ratio, patient preferences, and costs. Finally, the panel, including representatives from a patient advocate group (International Kidney Cancer Coalition) voted and reached a consensus to not recommend adjuvant therapy with sunitinib for patients with high-risk RCC after nephrectomy. PATIENT SUMMARY: In two studies, sunitinib was given for 1 yr and compared to no active treatment (placebo) in patients who had their kidney tumour removed and who had a high risk of cancer coming back after surgery. Although one study demonstrated that 1 yr of sunitinib therapy resulted in a 1.2-yr longer time before the disease recurred, the other study did not show a benefit and it has not been shown that patients live longer. Despite having been diagnosed with high-risk disease, many patients remain without recurrence, and the side effects of sunitinib are high. Therefore, the panel members, including patient representatives, do not recommend sunitinib after tumour removal in these patients.
650    _2
$a protinádorové látky $x terapeutické užití $7 D000970
650    _2
$a karcinom z renálních buněk $x farmakoterapie $x patologie $7 D002292
650    _2
$a adjuvantní chemoterapie $7 D017024
650    _2
$a Evropa $7 D005060
650    _2
$a lidé $7 D006801
650    _2
$a indoly $x terapeutické užití $7 D007211
650    _2
$a nádory ledvin $x farmakoterapie $x patologie $7 D007680
650    12
$a nefrektomie $7 D009392
650    _2
$a směrnice pro lékařskou praxi jako téma $7 D017410
650    _2
$a pyrroly $x terapeutické užití $7 D011758
650    _2
$a společnosti lékařské $7 D012955
650    _2
$a urologie $7 D014572
655    _2
$a časopisecké články $7 D016428
700    1_
$a Albiges, Laurence $u Department of Cancer Medicine, Institut Gustave Roussy, Villejuif, France.
700    1_
$a Ljungberg, Börje $u Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden.
700    1_
$a Bensalah, Karim $u Department of Urology, University of Rennes, Rennes, France.
700    1_
$a Dabestani, Saeed $u Department of Urology, Skåne University Hospital, Malmö, Sweden.
700    1_
$a Giles, Rachel H $u Patient Advocacy, International Kidney Cancer Coalition, Duivendrecht, The Netherlands; University Medical Centre Utrecht, Nephrology Department, Utrecht, The Netherlands.
700    1_
$a Hofmann, Fabian $u Department of Urology, Sunderby Hospital, Sunderby, Sweden.
700    1_
$a Hora, Milan $u Department of Urology, Faculty Hospital and Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Kuczyk, Markus A $u Department of Urology and Urologic Oncology, Hannover Medical School, Hannover, Germany.
700    1_
$a Lam, Thomas B $u Department of Urology, Aberdeen Royal Infirmary, Aberdeen, UK; Academic Urology Unit, University of Aberdeen, Aberdeen, UK.
700    1_
$a Marconi, Lorenzo $u Department of Urology, Coimbra University Hospital, Coimbra, Portugal.
700    1_
$a Merseburger, Axel S $u Department of Urology, University Hospital Schleswig-Holstein, Lübeck, Germany.
700    1_
$a Staehler, Michael $u Department of Urology, Ludwig-Maximilians University, Munich, Germany.
700    1_
$a Volpe, Alessandro $u Division of Urology, Maggiore della Carità Hospital, University of Eastern Piedmont, Novara, Italy.
700    1_
$a Powles, Thomas $u The Royal Free NHS Trust and Barts Cancer Institute, Queen Mary University of London, London, UK.
773    0_
$w MED00001669 $t European urology $x 1873-7560 $g Roč. 71, č. 5 (2017), s. 719-722
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27986369 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180404 $b ABA008
991    __
$a 20180404142440 $b ABA008
999    __
$a ok $b bmc $g 1288380 $s 1007707
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 71 $c 5 $d 719-722 $e 20161213 $i 1873-7560 $m European urology $n Eur Urol $x MED00001669
LZP    __
$a Pubmed-20180404
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace